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Background: The use of imatinib mesylate is associated with a progression free survival of 41 months in first line
treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that
adjuvant imatinib treatment improves the recurrence-free survival in patients with GIST. Current recommendations
include 1 year adjuvant treatment in GIST patients at risk but active studies explore different durations of treatment
with an interval of up to 5 years. While the most frequent adverse events (AEs) are blood count alterations,
abdominal discomfort and edema, the occurrence of grade 3 or 4 increase of AST or ALT is specified with 2.1% and
2.7% respectively.
Case presentation: We report a 49-year old male with a gastrointestinal stromal tumor (GIST) of the small bowel
who developed liver cirrhosis under adjuvant imatinib treatment.
Conclusions: Our report supports the notion that imatinib-induced hepatotoxicity may lead to acute liver damage
with subsequent cirrhotic remodelling. Patients developing grade 3 or 4 hepatotoxicity during imatinib treatment
should therefore be carefully evaluated for chronic liver disease.
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The selective tyrosine kinase inhibitor imatinib mesylate
has dramatically influenced the treatment of chronic
myeloid leukemia (CML) and gastrointestinal stromal
tumors (GIST). First line treatment of metastatic or lo-
cally advanced GIST with imatinib is currently asso-
ciated with a PFS of 41 months [1]. The basis for
imatinib in the treatment of GIST has been further broa-
dened by other studies, which showed that adjuvant
treatment with imatinib improves the recurrence-free
survival in patients with GIST [2,3]. As imatinib treat-
ment is commonly well tolerated, the most frequent ad-
verse events (AEs) are blood count alterations,
abdominal discomfort and edema. The adjuvant Z9100
GIST trial reported on grade 3 or 4 increase of AST or
ALT in 2.1% and 2.7% respectively, indicating the rather
rare occurrence of hepatotoxicity [3]. With the imple-
mentation of imatinib for adjuvant treatment in GIST* Correspondence: seidel.christoph@mh-hannover.de
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reproduction in any medium, provided the ormore patients are exposed to imatinib, which may also
increase the occurrence of imatinib-induced liver dam-
age. Current recommendations include 1 year adjuvant
treatment in GIST patients at risk, but active studies
explore different durations of treatment with an interval
of up to 5 years duration. We report on a case with
liver cirrhosis in a patient with advanced GIST and
high-risk of recurrence during adjuvant treatment with
imatinib.
Case presentation
A 49-year old male patient presented with flank pain
and hematuria. The CT scan showed a large pelvic
tumor 18 cm in diameter (Figure 1). A biopsy was per-
formed and the pathologic examination revealed a spin-
dle cell tumor with co-expression of CD117 and S100
protein, as well as a point mutation in c-kit exon 11,
consistent with the diagnosis GIST. Due to the large
tumor size, neoadjuvant therapy with imatinib 400 mg
daily was initiated. After 6 months of treatment, the pa-
tient developed grade 3 hepatotoxicity with ALT and
AST elevations from normal values to 882 U/l and 383
U/l, and an elevated bilirubin of 25 umol/l. Imatinib wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CT scan of the patient. GIST of the small bowel 18 x
10 cm in size when it was first diagnosed prior nedoadjuvant
treatment.
Figure 3 Development of transaminases under adjuvant
imatinib treatment.
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normal limits. Treatment was then continued at 400 mg
OD and sustained tumor shrinkage was seen in subse-
quent CT scans. After 16 months of neoadjuvant therapy
tumor shrinkage ceased and tumor size was reduced
from 18 cm to 14 cm (22% reduction). A complete tumor
resection was performed at that time. Consistent with
the clinical response, the pathological examination
revealed a tumor regression of 20% (Figure 2) with low
expression of proliferation markers (MIB <1%). Due to
the high risk of recurrence, adjuvant therapy with imati-
nib 400 mg OD was initiated. After 7 months of adjuvant
treatment, grade 4 hepatotoxicity developed with an ALT
1837 U/l and AST 1022 U/l (Figure 3) and an elevatedFigure 2 Photomicrograph of the GIST, (Hematoxylin– eosin;
original magnification, x200. Tumor regression of 20% under
neo-adjuvant treatment.bilirubin of 90 umol/l. Imatinib was paused for a total
duration of 8 weeks, and subsequently the elevated trans-
aminases declined to values within normal limits. Subse-
quent re-challenge of imatinib was associated with
another episode of hepatotoxicity after 14 days of re-ex-
posure. A corresponding MRI showed the development
of cirrhotic changes of the liver (Figure 4), which had
been absent at the previous MRI 3 months before.
Other possible causes of liver damage, including metas-
tasis, alcoholic liver disease, hepatitis A, B, C, and E,
autoimmune hepatitis and metabolic disorders were
excluded. Imatinib was discontinued permanently and
the transaminases returned to normal values within
6 months. Fifteen months after discontinuation of ima-
tinib the patient is still without relapse, but cirrhotic
changes of the liver remained sustained on MRI.Figure 4 MRI of the liver. One month after discontinuing adjuvant
treatment MRI shows clearly cirrhotic changes of the parenchyma.
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To our knowledge this is the first case, which reports on
the development of liver cirrhosis during adjuvant imati-
nib treatment in a patient with GIST. Hepatotoxicity has
been observed in about 2–5% of patients receiving imati-
nib [4-6]. Most of them present with mild temporary
liver enzyme elevations, which resolve after dose reduc-
tions or discontinuation of imatinib treatment [7,8].
However, acute liver failure has also been reported spor-
adically during imatinib treatment [9-11]. Histologic
changes have been described in some of these cases and
consist of inflammation, fatty degeneration, or necrosis
of the liver [10,12,13]. Due to the transient nature of
toxicity, re-exposure to imatinib is warranted in most
cases [14]. Prospective studies in patients with pre-existing
liver disease showed that imatinib can be administered
safely in these patients, indicating a different mechanism
for hepatic toxicity [15,16]. However, late changes have
been recognized in a patient with CML who was diag-
nosed with liver cirrhosis one year after cessation of
treatment due to imatinib-induced acute liver failure
[14]. Therefore a close follow up should be mandatory.
In asymptomatic patients constant liver enzyme mea-
surements should be adequate. If cirrhotic changes
already occurred, liver enzyme quantifications every
3 months with ultrasound of the abdomen and Alpha-
Fatal Protein measurements twice a year are performed
at our institution. If signs of consecutive liver damage
without evident morphological changes of the paren-
chyma occur, transient elastography could represent an
elegant screening method [17].
As we move forward to adjuvant therapy in GIST, a
much larger proportion of patients will receive drug ex-
posure and currently the ideal duration of adjuvant ima-
tinib treatment in high risk GIST remains undefined.
The work of Dematteo et al. indicates that the recur-
rence free survival seems to adapt after a treatment free
interval of 18 months. To determine the ideal period of
adjuvant imatinib treatment prospectively, clinical trials
are conducted to test the efficacy of a prolonged expos-
ure to adjuvant imatinib treatment in GIST for 5 years
(NCT00867113) or to evaluate the effects of 12 months
versus 36 months (NCT00116935).
Conclusion
Our report supports the notion that chronic liver disease
can be a consequence of imatinib-induced hepatotox-
icity. In consequence a careful follow-up strategy should
be implemented for patients with grade 3 or 4 hepatic
toxicity.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanyingimages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Acknowledgement
Publication was assisted by the project "Open-Access-Publizieren" of the
Deutsche Forschungsgemeinschaft (DFG).
Author details
1Department of Hematology, Hemostasis, Oncology and Stem cell
transplantation, Hannover Medical School, Carl-Neuberg Strasse 1, 30625
Hannover, Germany. 2Department of Gastroenterology, Hepatology and
Endocrinology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625
Hannover, Germany. 3Institute of Pathology, Hannover Medical School,
Oncology and Stem cell transplantation,, Carl-Neuberg Strasse 1, 30625
Hannover, Germany.
Authors’ contribution
CS: reviewed the literature, drafted and edited the manuscript; MF: drafted
and edited the manuscript; FL: processed and provided pathology; HB:
Helped in editing the manuscript; gave advice in terms of gastroenterologic
problems; AG: drafted and edited the manuscript; VG: reviewed the literature,
drafted and edited the manuscript All authors were involved in the patient
active management. All authors read and approved the final manuscript.
Received: 4 October 2011 Accepted: 21 May 2012
Published: 21 May 2012
References
1. Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-
Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O: Phase II
study of oral masitinib mesilate in imatinib-naïve patients with locally
advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J
Cancer 2010, 46:1344–1351.
2. Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bümming P, Nilsson
O, Andersson J, Ahlman H: Adjuvant imatinib treatment improves
recurrence-free survival in patients with high-risk gastrointestinal
stromal tumours (GIST). Br J Cancer 2007, 96:1656–1658.
3. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD,
Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter
MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology
Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib
mesylate after resection of localised, primary gastrointestinal stromal
tumour: a randomised, double-blind, placebo-controlled trial. Lancet
2009, 373:1097–1104.
4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F,
Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL,
Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A,
Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R,
Druker BJ, IRIS Investigators: Imatinib compared with interferon and
lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid
leukemia. N Engl J Med 2003, 348:994–1004.
5. Fuster F, Medina L, Vallansot R, Granell M, Brugeuera M: Imatinib induced
toxic hepatitis: description of two cases and review of the literature.
Gastroenterol Hepatol 2007, 30:525–530.
6. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot
F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann
OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese
S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL: Imatinib induces
durable hematologic and cytogenetic responses in patients with
accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002, 99:1928–1937.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB,
Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of
a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid
leukemia. N Engl J Med 2001, 344:1031–1037.
8. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson
K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, KM U, Staten AM,
Pazdur R: Approval summary for imatinib mesylate capsules in the
Seidel et al. BMC Cancer 2012, 12:186 Page 4 of 4
http://www.biomedcentral.com/1471-2407/12/186treatment of chronic myelogenous leukemia. Clin Cancer Res 2002,
8:935–942.
9. Ridruejo Ezequiel, Cacchione Roberto, Villamil Alejandra G, Marciano
Sebastián, Gadano Adrián C, Mandó Oscar G: Imatinib-induced fatal acute
liver failure. World J Gastroenterol 2007, 13:6608–6611.
10. Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M,
Buyukberber S: Imatinib mesylate-induced acute liver failure in a patient
with gastrointestinal stromal tumors. Med Oncol 2010, 27:768–773.
11. Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M: Imatinib
mesylate-induced acute hepatitis in a patient treated for gastrointestinal
stromal tumour. Eur J Gastroenterol Hepatol 2006, 18:785–787.
12. Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, Choi MY,
Cho MS, Mun YC, Nam E, Lee SN, Seong CM: Early imatinib-mesylate-
induced hepatotoxicity in chronic myelogenous leukaemia. Acta
Haematol 2007, 118:205–208.
13. Spataro V: Nilotinib in a patient with postnecrotic liver cirrhosis related
to imatinib. J Clin Oncol 2011, 29:e50–e52.
14. Joensuu H, Trent JC, Reichardt P: Practical management of tyrosine kinase
inhibitor-associated side effects in GIST. Canc Treat Rev 2001, 37:75–88.
15. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J,
Pierce S, Rios MB, Cortes J: Imatinib front-line therapy is safe and effective
in patients with chronic myelogenous leukemia with pre-existing liver
and/or renal dysfunction. Cancer 2010, 116:3152–3159.
16. Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso
PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP,
Hayes MJ, Peng B, Ivy SP, National Cancer Institute Organ Dysfunction
Working Group: Phase I and pharmacokinetic study of imatinib mesylate
in patients with advanced malignancies and varying degrees of liver
dysfunction: a study by the National Cancer Institute Organ Dysfunction
Working Group. J Clin Oncol 2008, 26:563–569.
17. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis
C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R: Transient
elastography: a new noninvasive method for assessment of hepatic
fibrosis. Ultrasound Med Biol 2003 Dec, 29(12):1705–1713.
doi:10.1186/1471-2407-12-186
Cite this article as: Seidel et al.: Imatinib-induced liver cirrhosis in a
patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer
2012 12:186.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
